Oral iron therapy in human subjects, comparative absorption between ferrous salts and iron polymaltose.
Iron absorption was directly compared between equivalent doses of ferrous salts and a polymaltose complex using a twin-isotope technique in which each individual acts as his own control. In the first study, bioavailability of iron from ferrous sulfate and the complex was defined at physiologic doses of 5 mg (Group 1: n = 14) and therapeutic doses of 50 mg (Group 2: n = 13). In Group 1, mean absorption from salt was 47.77% (SD 14.58%) and from polymaltose, 46.56% SD 17.07%). In Group 2, mean absorption from salt was 32.92% (SD 13.42%) and from polymaltose, 27.07% (SD 6.50%). In a second study, 100 mg of iron in a chewable formulation was used to compare absorption between equal doses of ferrous fumarate and the polymaltose complex. Mean absorption from salt was 10.25% (SD 6.89%) and from polymaltose 10.68% (SD 4.68%). At all three dosage levels, iron is equally available from salt or polymaltose for hemoglobin synthesis (p greater than 0.20), and absorption negatively correlated with plasma ferritin (p less than 0.01). These two materials may be used interchangeably in the treatment of patients with absolute iron deficiency.
D000042:Absorption; D001682:Biological Availability; D005290:Ferric Compounds / Q000008:administration & dosage / Q000378:metabolism*; D005293:Ferritins / Q000097:blood; D005296:Ferrous Compounds / Q000008:administration & dosage / Q000378:metabolism*; D006432:Hemochromatosis / Q000378:metabolism; D006801:Humans; D007501:Iron / Q000378:metabolism* / Q000627:therapeutic use*; D007504:Iron Radioisotopes; D013607:Tablets
D005290:Ferric Compounds; D005296:Ferrous Compounds; D007504:Iron Radioisotopes; D013607:Tablets; D005293:Ferritins; D007501:Iron; C031621:ferrous fumarate; C013276:teferrol